Full Press Release Details
Recognition underscores company's commitment to transparency and values
FRANKLIN LAKES, N.J. , Sept. 19, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced it has been ranked in the top 10 for overall transparency and awarded Best Code of Conduct among S&P 250 companies in the fifth annual U.S. Transparency Awards by Labrador, a global communications firm specializing in corporate disclosures.
"Particularly now, when stakeholders are evaluating the moral and ethical behaviors of companies, the code of conduct is the roadmap that provides insight into a company's values -- it guides and influences the behavior of its Board and employees," said Broc Romanek , industry-renowned expert and chair of the independent Transparency Scientific Committee, which will oversee the awards starting next year. "Among the many ways BD stood out among its peers, it provides a user-friendly interface, offers direct links to policies to ensure accessibility and includes an easy-to-understand graphic about the reporting process so that there can be no confusion."
Michelle Quinn , executive vice president and general counsel for BD said, "Transparency is a vital part of BD's strategy and being recognized for our transparency along with Best Code of Conduct in the U.S. Transparency Awards further demonstrates our commitment to doing what is right and continuing to build trust with our customers and their patients, investors, partners – and each other."
For more information on the U.S. Transparency Awards, visit TransparencyAwards.com or RealTransparentDisclosure.com; and to learn more about BD, visit BD.com .
About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 77,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD , please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo .
1All S&P 250 companies are ranked, with no need to apply and no fee. Each company receives its own confidential annual ranking. The list of companies was created in February 2023 , and the data collected between May 1 and August 15, 2023 .
2The criteria are objective and selected based on our unique methodology. For a list of the criteria and more information about the five pillars of transparency, visit www.transparencyawards.com .
| Contacts: | |
| Media : | Investors : |
| Jessica Offerjost | Adam Reiffe |
| BD Public Relations | BD Investor Relations |
| 201.258.0964 | 201.847.6927 |
| [email protected] | [email protected] |
SOURCE BD (Becton, Dickinson and Company)